Enzene Biosciences
Pune, India
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Enzene Biosciences
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Pune, India
- Modalities
- Monoclonal Antibody, Recombinant Protein, Biosimilars, Biologics (mammalian & microbial), Bispecific Antibody, Sterile Fill-Finish, Continuous Biomanufacturing (EnzeneX / FCCM)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Enzene Biosciences
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, Biosimilars, Biologics (mammalian & microbial), Bispecific Antibody, Sterile Fill-Finish, Continuous Biomanufacturing (EnzeneX / FCCM)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Enzene Biosciences launches biosimilar as rheumatoid arthritis medication - Healthcare Radius
India's Enzene Biosciences unveils $50M New Jersey plant project, plans to hire 300 - Fierce Pharma
Enzene Biosciences launches manufacturing base in US - financialexpress.com
Alkem subsidiary opens continuous biologics manufacturing facility - Manufacturing Chemist
CDMO player Enzene Biosciences opens new R&D centre in Pune - BioSpectrum India
Enzene inaugurates its cutting-edge R&D facility in Pune - ET HealthWorld
Enzene Biosciences inaugurates R&D Center with open lab setup in Pune - Express Pharma
Enzene Biosciences Launches New Drug Discovery Division - Contract Pharma
Enzene Biosciences Expanding to New Jersey Bio Manufacturing Plant - Contract Pharma
Enzene Biosciences launches first manufacturing base in US - BioSpectrum India
Frequently Asked Questions About Enzene Biosciences
What is Enzene Biosciences's CDMO Signal Score?
Enzene Biosciences has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Enzene Biosciences for a manufacturing program?
Use the free AI matchmaker to compare Enzene Biosciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish
Kemwell Biopharma, Bangalore
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product
Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
Chime Biologics
Wuhan, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Biosimilars, ADC (announced/expanding), Drug Product / Fill-Finish